Join        Login             Stock Quote

Questcor (QCOR): Treating MS

 April 18, 2011 01:24 PM

by Mike Cintolo, editor Cabot Top Ten Trader

Questcor Pharmaceutical (QCOR) focuses on treating dif?cult disorders, such as central nervous system problems, primarily multiple sclerosis, infantile spasms and nephrotic syndrome, when protein bleeds out of the kidneys.  

Its ?agship product is a drug called Acthar, which treats the side effects of multiple sclerosis.

Acthar is a drug of choice when the typical steroid treatment is ineffective or causes serious side effects. 

It's not cheap —one prescription costs $40,000 to $50,000 for the two week treatment period—partly because it's not a mass market drug.

Only 354 new prescriptions were written last quarter, the most ever for Questcor and up from 69 in the same quarter two years ago.  The company sees greater potential for Acthar given the annual relapses of MS patients, meaning sales could reach $2 billion.

To date, only about 400 of 8,000 neurologists who could write a prescription for the drug have, and a growing salesforce are out knocking on the non-prescribers' doors.  

In October, the FDA approved Acthar for infantile spasms for which it appears to be much more effective than the existing treatment, prednisone.  

Treatment of nephrotic syndrome with Acthar is still early, but there are few alternatives and the drug is FDA approved for that application.

QCOR gapped higher on April 5 after management indicated strong prescriptions of Acthar for MS, at 500 scripts over 115% higher than the prior quarter.

Shares saw huge volume on the news, the second trading day over seven million shares this year. (The average volume is one million shares.)

The leap from 15 to 18 makes shares a little hot right now, but any dips are buying opportunities.



Comments Closed

rss feed

Latest Stories

article imageTackling China's Debt Problem: Can Debt-Equity Conversions Help?

China’s high and rising corporate debt problem and how best to address it has received much attention read on...

article imageWill Job Growth Kill The Bear-Market Signal For Stocks?

It’s all about jobs now. Actually, it’s always been about jobs. But the stakes are even higher—perhaps more read on...

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.